Finance
Drugmaker Rovi's net profit rises on higher Okedi, heparin sales
Published by Global Banking & Finance Review®
Posted on February 25, 2026
2 min readLast updated: February 25, 2026
Quick Summary
Rovi posted a 3% rise in 2025 net profit to €140.4m as Okedi and heparins offset CDMO weakness; it proposes a €0.9594 dividend and sees 2026 revenue growing high single to low double digits. (marketscreener.com)
Rovi Net Profit Up 3% on Strong Okedi and Heparin Sales in 2025
Okedi and Heparin Sales
Net Profit Up 3%
Earnings and Sales Drivers
Feb 25 (Reuters) - Spanish drugmaker Laboratorios Farmaceuticos Rovi said on Wednesday its 2025 net profit rose 3% as higher sales of its schizophrenia drug Okedi and heparin products - as well as recognition of R&D aid - offset a decline in contract manufacturing revenue.
* Full-year net profit rose to 140.4 million euros, whileoperating revenue fell 3% to 743.5 million euros * CDMO revenue dropped 20% to 269.5 million euros onnegligible Moderna-related revenue and lower production volumesfor Moderna * Specialty pharmaceutical revenue increased 11% to 473.9million euros, driven by a 97% rise in Okedi sales and 7% in theheparin franchise, which includes low molecular weight heparins(LMWH) and other heparins * Gross profit rose 3% to 494.7 million euros, supported by36.3 million euros in R&D aid and lower LMWH raw material prices * Rovi will propose a dividend of 0.96 euros per share, apayout of around 35% * It expects 2026 operating revenue to grow by a highsingle-digit to low double-digit percentageReporting and Editing Credits
(Reporting by Marta Serafinko in Gdansk; Editing by David Latona)
Key Takeaways
- •Rovi's 2025 net profit increased 3% to €140.4m. (marketscreener.com)
- •Specialty pharma revenue grew 11%, with Okedi sales up 97% and heparins up 7%. (europapress.es)
- •CDMO revenue declined amid reduced vaccine-related volumes from Moderna. (rovi.es)
- •Gross profit rose 3% to €494.7m, aided by €36.3m in R&D aid and lower LMWH raw material prices. (europapress.es)
- •Rovi proposes a €0.9594/share dividend (~35% payout) and guides 2026 operating revenue to rise high single- to low double-digit. (marketscreener.com)
Frequently Asked Questions about Drugmaker Rovi's net profit rises on higher Okedi, heparin sales
1What is the main topic?
Rovi reported 2025 results: net profit up 3% to €140.4m as growth in Okedi and heparins offset weaker CDMO revenue. It also proposed a dividend and issued 2026 growth guidance. (marketscreener.com)
2How did Okedi and the heparin franchise perform?
Okedi sales jumped 97% to €56.7m, while the heparin franchise rose 7% to €266.8m in 2025, driven by stronger partner orders. (europapress.es)
3What is Rovi’s outlook for 2026?
Rovi expects operating revenue to increase by a high single- to low double-digit percentage, with potential support from a pending Bristol Myers Squibb manufacturing deal. (marketscreener.com)
